KNSA
Kiniksa Pharmaceuticals LtdKey Statistics
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a commitment to redefining treatment paradigms, Kiniksa presents a compelling opportunity for institutional investors seeking exposure in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $677.56M |
| Gross Profit (TTM) | $370.35M |
| EBITDA | $78.78M |
| Operating Margin | 9.78% |
| Return on Equity | 11.70% |
| Return on Assets | 7.18% |
| Revenue/Share (TTM) | $9.13 |
| Book Value | $7.44 |
| Price-to-Book | 6.73 |
| Price-to-Sales (TTM) | 6.11 |
| EV/Revenue | 4.799 |
| EV/EBITDA | 38.13 |
| Quarterly Earnings Growth (YoY) | 550.00% |
| Quarterly Revenue Growth (YoY) | 65.00% |
| Shares Outstanding | $46.30M |
| Float | $40.06M |
| % Insiders | 3.57% |
| % Institutions | 103.52% |
Historical Volatility
Volatility is currently expanding